



---

CANCER PREVENTION & RESEARCH  
INSTITUTE OF TEXAS

**Oversight Committee Meeting Minutes**

February 18, 2015

**1. Meeting Called to Order**

A quorum being present, Dr. Rice called the Oversight Committee to order at 10:03 a.m.

**2. Roll Call /Excused Absences**

**Board Members Present:**

Dr. Bill Rice, Chair  
Mr. Pete Geren, Vice-Chair  
Ms. Amy Mitchell, Secretary  
Mr. Gerry Geistweidt  
Mr. Will Montgomery  
Dr. Cynthia Mulrow  
Dr. Craig Rosenfeld

**Board Members Absent:**

Mr. Angelos Angelou  
Mr. Ned Holmes

**MOTION:**

Dr. Rice asked for a motion to approve an excused absence for Mr. Angelou and Mr. Holmes.

Motion made by Mr. Geistweidt and seconded by Mr. Montgomery.

**MOTION CARRIED UNANIMOUSLY**

**3. Adoption of Minutes from the January 20, 2015, meeting. (TAB 1)**

**MOTION:**

Dr. Rice called for a motion to approve the minutes of the January 20, 2015, Oversight Committee meeting.

Motion made by Dr. Mulrow and seconded by Mr. Geistweidt.

**MOTION CARRIED UNANIMOUSLY**

#### **4. Chief Executive Officer Report (TAB 2)**

Mr. Roberts presented his report.

##### **Agency Move Update**

The agency will be closed on Friday, February 20, while the movers work, and is expected to be fully operational by Tuesday, February 23.

##### **Update on Legislative Activities**

CPRIT testified at the following committees:

- February 3, Senate Finance Committee: CPRIT testified regarding the agency's 2016-17 budget request.
- February 11, Senate Health and Human Services Committee: CPRIT testified on Senate Bill 197 which would require CPRIT to develop a plan for the agency to be self-sufficient by 2021.
- February 16, House Committee on Appropriations Subcommittee on Article: CPRIT gave a brief overview of current budget request.

Other legislation of interest:

- House Bill 1282 by Zerwas would require CPRIT to collaborate with the Department of State Health Services on a strategic plan designed to reduce HPV-related morbidity and mortality.
- The Governor's Proposed State Budget for FY 2016-17 states that an amount of \$400 million, up to \$540 million, of CPRIT's budget be reserved for institutions of higher education to help fund academic research and the recruitment of nationally recognized cancer researchers to Texas universities. Mr. Roberts will follow up with the Governor's staff for clarification.

##### **Report on Funds Available for Grant Awards in FY 2015**

Mr. Roberts noted current available funds for grants this fiscal year is \$105.8 million. At the May 2015 meeting, staff will present recommended priorities to the Oversight Committee (OC) for consideration in making grant funding decisions. Dr. Mulrow asked for an explanation of the prioritization process. A question was asked whether it could be possible to fund one program's applications ranking lower than other programs' applications.

There was no further discussion nor questions for Mr. Roberts.

**5. Public Comments (taken out of order)**

Dr. Rice announced one request for public comment had been received from Ms. Annette Leslie, who has served on CPRIT's Advisory Committee for Childhood Cancer since 2010.

Ms. Leslie gave an update on her federal activities and stated she believes that CPRIT has the opportunity to be the catalyst for change in cancer for children.

**6. Chief Compliance Officer Report (TAB 3)**

Mr. David Reisman, Chief Compliance Officer, updated the Oversight Committee on the following items:

- Monitoring Submission Status of Required Grant Recipient Reports.
- Grantee Desk Reviews and Site Visits.

Mr. Reisman noted the deadline for submitting Personal Financial Reports to the Texas Ethics Commission is April 30, 2015.

**7. Chief Operating Officer Report (Tab 4)**

Ms. Heidi McConnell, Chief Operating Officer, updated the Oversight Committee on the following items:

- FY 2015, Quarter 1 Operating Budget.
- FY 2015, Quarter 1 Performance Measures.
- Debt Issuance History.

Ms. McConnell also noted that staff is working on finalizing the Renaissance Hotel contract for CPRIT's 2015 Conference. She commented that none of the Oversight Committee members had reported a financial interest in the hotel, so the agency will move forward on the contract.

In response to an Oversight Committee member's question, Ms. McConnell provided an explanation of the performance measure reporting.

**8. Chief Prevention and Communications Officer Report – Communications Report (Tab 5) (00:50)**

Dr. Becky Garcia, Chief Prevention and Communications Officer, updated the Oversight Committee on the following communications activities:

- Summary of CPRIT media coverage over the last quarter.
- The American Cancer Society public opinion poll results.
- CPRIT's social media campaign, including Facebook and Twitter.
- Completion of CPRIT's Annual Report.
- Preparation of an accomplishments report.

- Preparation of a basic slide deck that can be used when members need to present information, in addition to having staff available to assist in customizing materials.
- Continuing preparations for the screening of the PBS documentary.
- CPRIT conference contract is ready for signature so staff now can move forward with speakers.

In response to a question about whether grantees will be invited to the CPRIT conference Dr. Garcia responded that they are invited to send up to two people per grant.

**9. Chief Prevention and Communications Officer Report – Prevention Program Report (Tab 6) (01:00)**

Dr. Garcia updated the Oversight Committee on the following Prevention items:

- No Prevention Program grant awards are before the committee today.
- Prevention Peer Review Meeting, February 23-25, 2015 in Dallas.
- RFAs for April are currently being revised to add screening for Hepatitis B and C for prevention of liver cancer.
- Discussion is continuing with the College of American Pathologists about collaboration on a project called *See, Test & Treat*, a program of community-based cervical and breast cancer screening for underserved populations in Texas.

There were no questions from the Oversight Committee for Dr. Garcia.

**10. Chief Scientific Officer Report (Tab 7) (01:05)**

Dr. Margaret Kripke, Chief Scientific Officer, updated the Oversight Committee on the following scientific research activities:

- Scientific Research Peer Review Meeting will take place in Dallas on March 8-18, 2015.
- By the end of the week, the next set of RFAs will be issued, which will include new research training awards or existing awards due to expire and Individual Investigator awards, including targeted and untargeted awards. The targeted awards will be for prevention and early detection, for childhood and adolescent cancers, and a new one for computational biology, in accordance with the priorities set by the Oversight Committee.

**Academic Research Grant Award Recommendations:**

Dr. Kripke stated that 51 applications were being recommended for funding, for a combined amount of \$56,922,094.

An Oversight Committee member asked that the priorities be addressed in the recruitment RFAs as they are in other RFAs and Dr. Rice said it should be taken up in the next Research Subcommittee.

## Academic Research Grant Award Slate

App ID	Award Mechanism	Organization	Application Title	Budget
RP150006	IIRACCA	The University of Texas M. D. Anderson Cancer Center	Defining and Treating Targetable Lesions in AYA Acute Lymphoblastic Leukemia	\$1,989,950
RP150014	IIRAP	The University of Texas Health Science Center at Houston	Multi-component interventions for patients and providers to increase HPV vaccination in a network of pediatric clinics in Houston, TX	\$2,498,986
RP150030	IIRA	The University of Texas M. D. Anderson Cancer Center	Exploring molecular and immune mechanisms of response and resistance to combined BRAF/MEK inhibition in patients with high-risk resectable metastatic melanoma	\$900,000
RP150032	IIRACCA	Baylor College of Medicine	Developing New Combinatory Therapies for Pediatric High Grade Glioma	\$1,945,940
RP150053*	IIRA	The University of Texas Southwestern Medical Center	Mechanisms of nuclear import and export in cancer	\$900,000
RP150079	IIRA	The University of Texas M. D. Anderson Cancer Center	Elucidating the evolution of the premalignant airway genome in space and time	\$886,173
RP150081	IIRACCA	Baylor College of Medicine	Genetic susceptibility to testicular germ cell tumors	\$1,406,791
RP150084	IIRA	The University of Texas M. D. Anderson Cancer Center	Role of PTEN feedback mechanism in cancer	\$900,000
RP150093	IIRA	The University of Texas M. D. Anderson Cancer Center	Targeting 17q23 amplicon in HER2-positive Breast Cancer	\$828,242
RP150094	IIRA	The University of Texas M. D. Anderson Cancer Center	Investigating the regulation of miRNA and lncRNAs by p63 in mammary tumor progression and metastasis	\$900,000
RP150102	IIRA	The University of Texas M. D. Anderson Cancer Center	Genome stability and immune diversity controlled by the POLQ pathway	\$900,000
RP150129	IIRACCA	Baylor College of Medicine	Drug Discovery and Mechanistic Studies of Protein Methylation Targeting Leukemia	\$1,733,813
RP150148	IIRA	The University of Texas M. D. Anderson Cancer Center	Identifying Drivers of Lung Metastasis in Triple Negative Breast Cancer	\$899,637
RP150164	IIRACCA	The University of Texas Southwestern Medical Center	Using imaging and computational tools to improve risk stratification in children with bone cancer	\$1,290,442
RP150166	IIRA	The University of Texas Health Science Center at San Antonio	Prostate Cancer Chemoprevention with Resveratrol	\$900,000
RP150179	IIRA	The University of Texas M. D. Anderson Cancer Center	Regulation of dormancy of metastatic prostate cancer cells by bone microenvironment	\$900,000
RP150195	IIRAP	The University of Texas M. D. Anderson Cancer Center	Mechanisms of DHA and EPA differential effects on colon cancer chemoprevention	\$920,926

RP150197	IIRA	Baylor College of Medicine	Understanding How NCOA6 Suppresses Endometrial Cancer by Inhibiting the Wnt/beta-Catenin Pathway	\$886,524
RP150224	IIRA	The University of Texas M. D. Anderson Cancer Center	Discovering the molecular mechanisms that determine replicative lifespan	\$892,104
RP150228	IIRAP	The University of Texas M. D. Anderson Cancer Center	Varenicline and Combined NRT for Initial Smoking Cessation and Rescue Treatment in Smokers: A Randomized Pilot Trial	\$1,493,464
RP150230	IIRA	The University of Texas Health Science Center at Houston	Counteracting tumor evasion of antibody immunity by a novel therapeutic strategy	\$900,000
RP150231	IIRA	The University of Texas M. D. Anderson Cancer Center	Function of Fibroblasts and Collagen I in Pancreas Cancer	\$898,811
RP150232	IIRA	Baylor College of Medicine	The Role of Progesterone Receptor in Early Stage Breast Cancer.	\$864,661
RP150235	IIRA	The University of Texas M. D. Anderson Cancer Center	Role of TBK1 in Regulating Dendritic Cell Function and Antitumor Immunity.	\$876,958
RP150242	IIRA	The University of Texas Southwestern Medical Center	Functional and structural characterization of a small chemical compound that arrests glioma stem cell growth with high activity and specificity	\$900,000
RP150245	IIRA	The University of Texas M. D. Anderson Cancer Center	EGFR Arginine Methylations: Biomarkers for Cetuximab Resistance in colon cancer	\$900,000
RP150277	IIRA	The University of Texas Health Science Center at San Antonio	Vertical targeting of the B cell receptor in leukemia and lymphoma	\$899,879
RP150282	IIRA	The University of Texas M. D. Anderson Cancer Center	Mechanisms of de novo and acquired resistance to therapeutic treatment of bone-metastatic prostate cancer	\$900,000
RP150292	IIRA	Baylor College of Medicine	Broad Shortening of 3' UTRs in Human Cancers: Methods, Target Genes and Functional Consequences	\$900,000
RP150293	IIRA	The University of Texas M. D. Anderson Cancer Center	Identification of clinically relevant targets for radiosensitization	\$899,280
RP150301	IIRACCA	The University of Texas M. D. Anderson Cancer Center	Epigenetics in Medulloblastoma Development and Therapeutics	\$1,871,708
RP150316	IIRA	The University of Texas M. D. Anderson Cancer Center	T-cell activating immunotherapy for indolent B-cell malignancies	\$852,595
RP150319	IIRA	The University of Texas M. D. Anderson Cancer Center	Leukemia inhibitory factor receptor signaling and function in cancer	\$900,000
RP150334	IIRACCA	Baylor College of Medicine	Personalized Functionalization of Pediatric High Grade Glioma	\$1,820,319
RP150343	IIRACCA	University of Houston	An ultra-sensitive nanomagnetic sensor for the early detection of anaplastic large cell lymphoma	\$1,929,710

RP150346	IIRA	The University of Texas at Austin	Targeting Twist1 for Prevention and Treatment of Non-Melanoma Skin Cancer	\$900,000
RP150356	IIRA	The University of Texas Southwestern Medical Center	Peripheral nerve tolerance to single-session stereotactic irradiation	\$897,779
RP150386	IIRA	The University of Texas Southwestern Medical Center	A Phase I Trial of Stereotactic Hypofractionated RadioAblative (HYDRA) Treatment of Advanced Laryngeal Cancer	\$860,540
RP150403	IIRA	The University of Texas M. D. Anderson Cancer Center	On the role of DEAR1 in the regulation of cell polarity and progression from DCIS to invasive breast cancer	\$899,846
RP150405	IIRA	The University of Texas M. D. Anderson Cancer Center	Tumor Cell Epithelial-Mesenchymal Transition in Regulating Immunosuppression and Metastasis in Lung Cancer	\$900,000
RP150408****	IIRA	The University of Texas Health Science Center at San Antonio	Cellular mechanisms of chemotherapy- induced peripheral neuropathy	\$844,746
RP150416	IIRACCA	Texas Tech University Health Sciences Center	Translational Investigations On Fenretinide and Safingol For Pediatric Cancer Use	\$1,999,415
RP150421	IIRAP	Texas Engineering Experiment Station	High-throughput Screening and Detection of Circulating Tumor Cells	\$1,135,450
RP150440	IIRA	Baylor College of Medicine	Effects of hormonal therapy on subclonal evolution of breast tumors with ESR1 mutations	\$899,805
RP150445**	IIRACCA	The University of Texas Health Science Center at San Antonio	Ewing's sarcoma, a homologous recombination defective disease	\$2,000,000
RP150449	IIRAP	The University of Texas Medical Branch at Galveston	Noninvasive multiscale imaging for optical biopsy in epithelial cancers	\$852,748
RP150451***	IIRA	Baylor College of Medicine	SRC-2 driven "Metabolic Switch" in metastatic prostate cancer- Prognostic and Therapeutic implications	\$900,000
RP150454	IIRA	Texas A&M University	Tumor Suppression Through the cGAMP/STING Pathway	\$900,000
RP150456	IIRA	The University of Texas Southwestern Medical Center	TAMU-UT Southwestern Partnership for Breast Imaging and Spectroscopy at 7 Tesla	\$897,311
RP150485	IIRA	The University of Texas Southwestern Medical Center	Translating Online Adaptive Radiotherapy from Lab to Clinical Practice	\$858,356
RP150498	IIRA	The University of Texas Southwestern Medical Center	Harnessing the Cytosolic DNA Sensing Pathway for Cancer Immunotherapy	\$889,185

\* RP150053 - Budget will be adjusted down during contracting to accommodate a change in the Scope of Work (removal of specific Aim 3) as recommended by the peer review panel. The total amount requested was \$900,000.

\*\*RP150445 - Budget will be adjusted down during contracting to accommodate a reduction in personnel and associated supplies and materials as recommended by the peer review panel. The total amount requested was \$2,000,000.

\*\*\*RP150451 - Budget will be adjusted down during contracting to accommodate a change in the Scope of Work (removal of specific Aim 3) as recommended by the peer review panel. The total amount requested was \$900,000.

\*\*\*\*RP150408 - Budget will be adjusted down during contracting to accommodate a change in the Scope of Work (removal of specific Aim 3) as recommended by the peer review panel. The total amount requested was \$844,746.

### **Academic Research Recruitment Grant Award Recommendations**

Dr. Kripke reported that three Recruitment of First-Time, Tenure-Track Faculty Members applications were being presented, for a combined amount of \$6,000,000.

#### **Academic Research Recruitment Grant Award Slate**

<b>App ID</b>	<b>Organization/Company</b>	<b>Candidate</b>	<b>Mechanism</b>	<b>Budget Requeste</b>
RR150032	The University of Texas Southwestern Medical Center	Dr. Jenna L. Jewell	RFT	\$2,000,000
RR150033	The University of Texas Southwestern Medical Center	Dr. Vincent S. Tagliabracci	RFT	\$2,000,000
RR150038	Texas A&M University	Dr. Jonathan T. Szczepanski	RFT	\$2,000,000

Dr. Kripke presented information showing the percentage of grants in each of the research areas, which show that the targeted RFAs are making a difference in the priority research areas of childhood and adolescent cancer, and prevention and early detection.

Dr. Kripke was asked by the Oversight Committee to make reporting on all the targeted priorities a part of her regular presentation to the committee and to provide a year-end report by category.

An Oversight Committee member asked if, when looking at the grant applications, the portfolio of grants already held by an investigator was considered.

#### **COMPLIANCE CERTIFICATION**

Mr. David Reisman, Chief Compliance Officer, presented his report on the Academic Research Awards review process and certified the recommended awards for Oversight Committee approval.

#### **CONFLICT OF INTEREST NOTIFICATIONS – Academic Research Grant Awards**

Dr. Rice noted for the record that Ms. Mitchell reported conflicts with applications submitted by the following institutions:

- Baylor College of Medicine
- The University of Texas at Austin
- The University of Texas Health Science Center at Houston
- The University of Texas Health Science Center at San Antonio
- The University of Texas Medical Branch at Galveston
- The University of Texas MD Anderson Cancer Center
- The University of Texas Southwestern Medical Center
- The University of Houston
- Texas Tech University Health Science Center
- Texas Engineering Experiment Station
- Texas A&M University

Dr. Rice stated that in accordance with CPRIT's rules, Ms. Mitchell was recused from the discussion or action on these applications. He then confirmed there were no other conflict of interest declarations for Oversight Committee members.

**MOTION:**

Dr. Rice called for a motion to approve each of the PIC's recommendations for individual investigator grant awards and award amounts, for applications submitted by:

- Baylor College of Medicine
- The University of Texas Health Science Center at Houston
- The University of Texas Health Science Center at San Antonio
- The University of Texas Medical Branch at Galveston
- The University of Texas MD Anderson Cancer Center
- The University of Texas Southwestern Medical Center
- The University of Houston
- Texas Tech University Health Science Center
- Texas Engineering Experiment Station
- Texas A&M University
- Texas University of Texas at Austin

Motion was made by Mr. Montgomery and seconded by Dr. Mulrow.

**MOTION CARRIED UNANIMOUSLY**

Dr. Rice noted for the record that Ms. Mitchell abstained from voting.

**CONFLICT OF INTEREST NOTIFICATIONS – Recruitment Grant Awards**

Dr. Rice noted for the record that Ms. Mitchell reports conflicts with applications submitted by the following institutions:

- The University of Texas Southwestern Medical Center
- Texas A&M University

In accordance with CPRIT's rules, Ms. Mitchell was recused from the discussion or action on these applications. He then confirmed there were no other conflict of interest declarations for Oversight Committee members.

Dr. Rice noted for the record that the candidate associated with RR150025 notified the institution after the PIC meeting that he has declined the appointment. Therefore the Oversight Committee will not vote on RR150025.

**MOTION:**

Dr. Rice called for a motion to approve each of the PIC's recommendations for recruitment grant awards and award amounts.

Motion by Mr. Montgomery and seconded by Mr. Geistweidt.

**MOTION CARRIED UNANIMOUSLY**

Dr. Rice noted for the record that Ms. Mitchell abstained from voting.

**MOTION:**

Having approved the PIC recommendations for the Individual Investigator and Recruitment grant awards, Dr. Rice called for a motion to delegate contract negotiation authority to the Chief Executive Officer and CPRIT staff and to authorize the Chief Executive Officer to sign the contracts on behalf of the Institute.

Motion by Mr. Geistweidt and seconded by Ms. Mitchell.

**MOTION CARRIED UNANIMOUSLY**

**11. Contract Management Overview(Tab 10) (Agenda Item 13 taken out of order.)**

Dr. Rice called on Heidi McConnell, Chief Operations Officer, to present an overview of CPRIT service contracts.

Ms. McConnell stated that an overview of the contracts was under TAB 10 in the meeting book materials, including a table showing the history of CPRIT service contracts (green highlights representing current service contracts).

Ms. McConnell clarified that in the table, the Oversight Committee is presented with all the significant contracts, though purchases such as travel, office supplies, and information technology, made through contracts negotiated by other state agencies (i.e., Comptroller's Office and the Department of Information Resources) are not included.

Ms. Kristen Doyle, General Counsel, stated that because of the pending Senate Bill 353 and Governor Abbott's letter to all state agencies asking them to implement its provisions to the extent possible, CPRIT is implementing the provision that prohibits an agency from contracting with an entity or person where there is a financial interest of a governing board member or key senior staff.

**Contract Management Training Required by Government Code §2262.0535**

Ms. Cameron Eckel advised the committee about the documentation needed to certify to the Comptroller's Office that members received the mandatory state contract training, which they were about to receive in the form of a webinar viewable to all in the meeting room.

**12. Personnel – Chief Executive Officer, Chief Scientific Officer, Chief Prevention and Communications Officer, Chief Operating Officer, Chief Advisor and General Counsel, and Chief Compliance Officer. (Agenda Item 23 taken out of order.)**

Dr Rice announced the Oversight Committee was going into closed session pursuant to Texas Open Meetings Act section 551.074 to deliberate the evaluation of public employees. Dr. Rice called the time at 1:00 p.m. and the meeting went into closed session.

After the closed session concluded, Dr. Rice called the meeting back to order at 1:59 p.m. He stated no further actions were required as a result of the closed session.

### **13. Chief Product Development Officer Report (Tab 8)**

Dr. Tom Goodman, Chief Product Development Officer, presented updates on the following program items:

- Follow-on Funding for CPRIT Product Development Research Grantees
- FY2015 Cycle 1 - Product Development Research Grants
- FY2015 Cycle 4 - Product Development Research Grant Applications
- Standard Revenue Sharing Terms and Conditions

#### **Early Translational Research Award Program Assignment:**

Dr. Goodman discussed the positioning of the ETRA program in the Product Development program instead of the Academic Research program. The Early Translational Research Awards (ETRA) were transferred to the Product Development Research Program in 2014. At the Oversight Committee meeting in November, 2014, the Oversight Committee discussed whether it was appropriate to retain the ETAs in the Product Development Program or to have the grants administered by the Academic Research Program. Dr. Goodman stated that having the Academic Research Program evaluate and administer ETAs would maintain consistency in the review process and contract terms, and data reporting between ETRA grants and all other research grants made to institutions of higher education. Mr. Roberts stated that he is more comfortable with returning them to the Academic Research program primarily because the grants are going to universities instead of companies. The adequacy of the peer reviewers in the Academic Research program could be addressed by adding more product development reviewers. Mr. Roberts said no specific action was required by the Oversight Committee members unless a different approach is desired. No further questions or comments on the ETRA program position.

#### **Grant Award Recommendations**

Dr. Goodman stated four applications were being recommended for product development research funding for a total cost of \$48.5 million.

Dr. Goodman responded to Oversight Committee questions, stating that money used by companies for matching funds was coming from various sources including from public funding and corporate sources. Dr. Goodman also reported that even though some of the contracts were approved earlier, all of the companies currently pending contract execution would receive the contract terms most recently approved and that feedback from four of the six affected companies has been positive. An OC member observed that it means the terms are not too onerous for the companies.

**Product Development Grant Award Slate**

<b>Application ID</b>	<b>Company Name</b>	<b>Project</b>	<b>Requested Budget</b>
DP150021	NanoTx Therapeutics	Development of Rhenium Nanoliposomes for Cancer Therapy	\$ 2,000,000
DP150029	Immatics Biotechnologies	Personalized Cellular Immunotherapy against Novel Cancer Targets	\$19,652,175
DP150031	Medicenna Therapeutics, Inc.	A Multi-Targeted Approach for Recurrent Glioblastoma and Other Aggressive Cancers: Exploiting the Potential of IL-4 Fusion Proteins Treatment of Cancer	\$14,140,090
DP150039	Armada Pharmaceuticals, Inc.	New Company Formation for the Development of Anti-Cancer Antibody – Drug Conjugate Therapeutics	\$12,750,000

**COMPLIANCE CERTIFICATION**

Mr. David Reisman, Chief Compliance Officer, presented his report on the Product Development review process and certified the recommended awards for Oversight Committee approval.

**CONFLICT OF INTEREST NOTIFICATIONS – New Company Product Development Awards**

Dr. Rice noted for the record that no Oversight Committee members reported conflicts of interest with any of the New Company Product Development applications being considered.

**MOTION:**

Dr. Rice called for a motion to approve each of the Program Integration Committee recommendations for New Company Product Development Research Awards and award amounts.

Motion made by Mr. Geistweidt and seconded by Mr. Montgomery.

**MOTION CARRIED UNANIMOUSLY**

**MOTION:**

Having approved the New Company Product Development Research Awards, Dr. Rice called for a motion to delegate contract negotiation authority to the Chief Executive Officer and CPRIT staff and to authorize the Chief Executive Officer to sign the contracts on behalf of CPRIT.

Motion by Mr. Montgomery and seconded by Mr. Geistweidt.

**MOTION CARRIED UNANIMOUSLY**

**MOTION:**

Dr. Rice called for a motion, pursuant to the General Appropriations Act, Article IX, Section 4.03(a), to authorize CPRIT to disburse grant funds via advance payments to the four Product Development Awards approved by the Oversight Committee above.

Motion by Mr. Montgomery and seconded by Dr. Rosenfeld.

**MOTION CARRIED UNANIMOUSLY**

**14. Scientific Research and Prevention Program Committee Appointments (Tab 9)**

Dr. Rice presented the February 13, 2015, Nominations Subcommittee report. Recommending approval of the CEO's three appointments to CPRIT's Scientific Research and Prevention programs committees.

**MOTION:**

Dr. Rice called for a motion to approve the Chief Executive Officer's appointments to the Scientific Research and Prevention programs committees.

Motion by Mr. Montgomery and seconded by Dr. Rosenfeld.

**MOTION CARRIED UNANIMOUSLY**

**15. Advisory Committee on Childhood Cancers—Annual Report (TAB 11) (02:20)**

Dr. Rice recognized Dr. Gail Tomlinson, Chair of the Advisory Committee on Childhood Cancers (ACCC), to present the Annual Report of the Advisory Committee.

Dr. Tomlinson gave the Oversight Committee an update on the ACCC's activities over the past year and their priorities for research, which include: brain tumors, metastatic bone tumors, acute myeloid leukemia, relapsed acute lymphocytic leukemia, high-risk neuroblastoma, and other relapsed solid tumors. Some of the ACCC's recommendations were: emphasis on multi-investigator/multi-institutional investigator-initiated research; recognition that the current limitation of one core facility application per institution may hinder opportunities for pediatric focus whereas permitting a second grant from institutions if their focus is pediatric cancer would be highly beneficial; development of clinical trials infrastructure for pediatrics.

An Oversight Committee member asked Dr. Kripke to consider allowing a second grant from institutions targeting certain cancers.

In response to questions, Dr. Tomlinson clarified that the diseases listed on the handout were not in priority order and she indicated that two top priorities are brain cancer and myeloid leukemia. Dr. Tomlinson also responded that extreme liability is not a hindrance to research because parents are desperate for new treatments.

**16. University Advisory Committee—Annual Report (TAB 12) (02:45)**

Dr. Rice recognized Dr. Mary Ann Ottinger, Vice Chair of the University Advisory Committee (UAC), to present the Advisory Committee’s annual report.

Dr. Ottinger gave the Oversight Committee an update on the UAC’s activities over the past year. Some of their recommendations are:

- Continuing recruitment awards
- Funding initiatives for research on diseases that disproportionately affect Texans, such as lung cancer, and obesity and diabetes which intersect with many cancers.
- Consider a mechanism to foster cooperative centers in regional and statewide infrastructure networks to help doctors, researchers and scientists keep abreast of all new technology.

An Oversight Committee member asked that the UAC develop some metrics for CPRIT to use to measure the success of the research it invests in, and that the UAC propose new and innovative areas of research that could be unique to Texas.

Dr. Ottinger responded to a question about how recruitment could be used to promote pediatric cancer research, stating it could be very useful but would like to inquire about hiring practices at the universities before making a statement.

**17. CEO Report Pursuant to Health & Safety Code § 102.260(c) (TAB13)**

Mr. Roberts referenced his memo on the FY2014 Report on the Merit and Progress of Programs Pursuant to Texas Health and Safety Code section 102-260(c) to report that the programs are functioning well and no action is required by the Oversight Committee at this time. An Oversight Committee member observed it is too soon to be reporting on the program progress against the program priorities that were approved in September, and asked if the report will be done again next year and include this information. Mr. Roberts said it would. There were no other comments or questions.

**18. Grant Compliance Monitoring Contract (TAB 14)**

Ms. McConnell said staff recommends moving forward with a grants compliance monitoring contract with CohnReznick for an amount not to exceed \$336,000 for the remainder of FY 2015, or approximately six months.

Dr. Rice presented the February 9, 2015, Audit Subcommittee report recommending that the Oversight Committee authorize the agency to move forward to contract with CohnReznick to provide services.

Dr. Rice stated for the record no Oversight Committee member or their family members reported a financial interest in the company CohnReznick, and that the General Counsel informed him that no financial interests were reported. He asked if there were any conflicts not yet reported and noted that no member reported a financial interest.

**MOTION:**

Dr. Rice called for a motion to authorize the agency to seek approval for a contract with CohnReznick to provide grant compliance monitoring services for an amount not to exceed \$336,000.

Motion made by Mr. Montgomery and seconded by Dr. Rosenfeld.

**MOTION CARRIED UNANIMOUSLY**

**19. Internal Audit Services Contract (TAB 15)**

Ms. McConnell stated that behind Tab 15 in the meeting materials was the staff recommendation to contract with Weaver and Tidwell for an amount not to exceed \$217,500 to provide internal audit services for FY 2015. She noted that GrantThornton, the current internal auditor, submitted a proposal which was the lowest bid. However, since they have been the auditor for five years, staff felt it appropriate to make a change at this time.

Dr. Rice gave the February 9, 2015, Audit Subcommittee report recommending that the Oversight Committee authorize the agency move forward to contract with Weaver and Tidwell to provide internal audit services.

Dr. Rice noted that the General Counsel informed him that no financial interests in Weaver and Tidwell were reported by Oversight Committee members or their family. Dr. Rice asked if anyone had an unreported financial interest and noted for the record that no member reported a financial interest.

**MOTION:**

Dr. Rice called for a motion to authorize the agency to seek approval for a contract with Weaver and Tidwell to provide internal audit services for an amount not to exceed \$217,500.

Motion made by Mr. Geistweidt and seconded by Mr. Rosenfeld.

**MOTION CARRIED UNANIMOUSLY**

**20. SRA International Contract Renewal for Pre- and Post-Award Grants Management Support Services (Tab 16)**

Ms. McConnell noted that behind Tab 16 in the meeting materials was the staff recommendation to move forward with exercising the 12-month renewal option for FY 2016 with SRA International for Pre- and Post-Award Grants Management Support Services.

Dr. Rice presented the February 9, 2015, Audit Subcommittee report recommending that the Oversight Committee approve the contract extension.

Dr. Rice noted for the record that the General Counsel informed him that no financial interests in SRA International were reported by Oversight Committee members or their family. Dr. Rice asked if anyone had an unreported financial interest and noted for the record that no member reported a financial interest.

**MOTION:**

Dr. Rice called for a motion to approve the Chief Executive Officer exercising the renewal option to extend SRA International's contract for fiscal year 2016.

Motion made by Mr. Geistweidt and seconded by Mr. Geren.

**MOTION CARRIED UNANIMOUSLY**

**21. Final Order Approving Amendments to 25 T.A.C. Chapter 703 (TAB 17)**

Ms. Kristen Doyle, General Counsel, presented the final orders approving changes to CPRIT's administrative rules, which he noted were located behind Tab 17 in the meeting materials. Ms. Doyle noted there were three rule changes:

§703.6(g). The change authorizes the Chief Compliance Officer to observe and report that the agency's grant review processes are consistently followed at peer review and review council meeting, including observance of CPRIT's established conflict of interest rules.

§703.11(b). The proposed rule change clarifies how a grantee should calculate the federal indirect cost rate when the institution's indirect cost rate changes during a project year.

§703.11(c). This amendment allows funds contributed by a subcontractor or subawardee to count towards the grantee's required matching funds.

Ms. Doyle stated that in December 2014 the rule changes had been posted for comments on the CPRIT website and in the *Texas Register*. The University of Texas MD Anderson Cancer Center submitted the only response to the request for public comments. As described in the proposed final order, one comment was not germane to this rulemaking change. The second comment, a request for clarification regarding the proposed rule change to §703.11(c), was addressed without changing the text of the proposed rule amendment.

Dr. Rice noted that there was a memo from the Board Governance Subcommittee in materials behind Tab 17 recommending approval of these rule changes. He asked if there were any questions for Ms. Doyle or the Board Governance Subcommittee. None was heard.

**MOTION:**

Dr. Rice called for a motion to approve the final orders adopting CPRIT's rule changes and to direct staff to file the orders with the Secretary of State.

Motion made by Mr. Geistweidt and seconded by Mr. Geren.

**MOTION CARRIED UNANIMOUSLY**

**22. Proposed Amendment to 25 T.A.C. Chapter 703 and Authorization to Publish in the *Texas Register* (TAB18)**

Ms. Doyle presented the proposed amendment which is behind Tab 18 in the meeting materials. She stated the proposed amendment to §703.11(c) provides guidance on how grant funds awarded by other granting organizations or entities may be credited towards CPRIT's matching fund requirement.

Dr. Rice noted there is a memo from the Board Governance Subcommittee Chair in members' meeting materials behind Tab 18 recommending approval of the proposed changes. He asked if there were any questions for Ms. Doyle or the Board Governance Subcommittee. None was heard.

**MOTION:**

Dr. Rice called for a motion to instruct staff to publish the proposed rule amendments to Chapter 703 in the *Texas Register* in accordance with the requirements of the Administrative Procedure Act.

Motion made by Mr. Montgomery and seconded by Dr. Rosenfeld.

**MOTION CARRIED UNANIMOUSLY**

**23. Subcommittee Business (Tab 19)**

**Contract Issues Subcommittee**

Mr. Roberts presented the Contract Issues Subcommittee charter provided behind Tab 19 of the meeting materials. The subcommittee was initially created to help with the development of economic terms for Product Development contracts. Staff and subcommittee members agree that the subcommittee should remain in place and meet on an as-needed basis.

Ms. Mitchell presented the February 5, 2015, the Board Governance subcommittee report recommending approval of the charter.

Dr. Rice asked if there were any questions for Ms. Mitchell or the Board Governance Subcommittee. None was heard.

**MOTION:**

Dr. Rice called for a motion to approve the charter of the Contract Issues Subcommittee.

Motion made by Mr. Geren and seconded by Dr. Mulrow.

**MOTION CARRIED UNANIMOUSLY**

**CPRIT FY 2014 Independent Financial Audit**

Dr. Rice stated the Audit Subcommittee met in December and February to discuss the FY 2014 Independent Financial Audit. CPRIT's independent auditors, McConnell and Jones, briefed the subcommittee.

**Outside Employment and Conflict of Interest Disclosure and Waiver**

Mr. Roberts presented his request for a conflict of interest waiver for Donald Brandy and said detailed information could be found behind Tab 19 in the meeting materials. Additionally, Mr. Brandy has requested approval to continue his outside employment as a referee for tennis tournaments held in and around Austin, including those held at universities. Mr. Roberts also stated he notified the Audit Subcommittee regarding his approval of Mr. Brandy's outside employment and it was discussed at the December 18, 2014, subcommittee meeting.

Dr. Rice asked if there were any further questions for Mr. Roberts and none was voiced.

**MOTION:**

Dr. Rice called for a motion to approve the conflict of interest waiver for Donald Brandy.

Motion made by Mr. Geistweidt and seconded by Mr. Geren

**MOTION CARRIED UNANIMOUSLY**

**Diversity Subcommittee Report**

Dr. Rice noted the Diversity Subcommittee report was located behind Tab 19 in the meeting materials and that Dr. Mulrow had no further comments.

**24. Consultation with General Counsel**

This agenda item was not taken up.

**25. Future Meeting Dates and Agenda Items (TAB 20)**

Dr. Rice told members that behind Tab 20 was a calendar with future subcommittee and open meeting dates through 2016. The next regular Oversight Committee meeting is scheduled for May 20, 2015. CPRIT staff will circulate a tentative agenda prior to the meeting.


26. Adjourn

**MOTION:**

There being no further business, Dr. Rice asked for a motion to adjourn the meeting at 3:25 p.m.

Motion by Mr. Geren made and seconded by Mr. Montgomery.

**MOTION CARRIED UNANIMOUSLY**

  
\_\_\_\_\_  
Signature

  
\_\_\_\_\_  
Date



CANCER PREVENTION & RESEARCH  
INSTITUTE OF TEXAS

**Conflict of Interest Disclosure – Oversight Committee Members  
For Applications Recommended for Consideration at February 18, 2015, Open Meeting**

**Conflict of Interest Disclosure - Amy Mitchell**

Academic Research (55)

RP150006, RP150014, RP150030, RP150032, RP150053, RP150079, RP150081, RP150084,  
RP150093, RP150094, RP150102, RP150129, RP150148, RP150164, RP150166, RP150179,  
RP150195, RP150197, RP150224, RP150228, RP150230, RP150231, RP150232, RP150235,  
RP150242, RP150245, RP150277, RP150282, RP150292, RP150293, RP150301, RP150316,  
RP150319, RP150334, RP150343, RP150346, RP150356, RP150386, RP150403, RP150405,  
RP150408, RP150416, RP150421, RP150440, RP150445, RP150449, RP150451, RP150454,  
RP150456, RP150485, RP150498, RR150025, RR150032, RR150033, RR150038

**Conflict of Interest Disclosure - Angelos Angelou**

Academic Research (1)

RP150346

By my signature, this list of reported conflicts of interest shall be included as the official record of conflicts of interest reported by Oversight Committee members for grant award recommendations considered at the November 19, 2014, Oversight Committee meeting.

Dr. William Rice, Presiding Officer, Oversight Committee

2-18-15

Date

Amy Mitchell, Secretary, Oversight Committee

2/18/15

Date



CANCER PREVENTION & RESEARCH  
INSTITUTE OF TEXAS

W 2-18-15  
Amy M. Rutchee  
2/18/15

February 6, 2015

Dear Oversight Committee Members:

I am pleased to present the Program Integration Committee's (PIC) unanimous recommendations for funding 59 grant applications totaling \$115,464,359 in grants. The PIC recommendations for 55 scientific research grant awards and four product development awards are attached.

Dr. Margaret Kripke, CPRIT's Chief Scientific Officer and Dr. Tom Goodman, CPRIT's Chief Product Development Officer, have prepared overviews of the scientific research and product development program slates to assist your evaluation of the recommended awards. The overviews are intended to provide a comprehensive summary of the recommended proposals with enough detail that you should be able to understand the substance of the proposal and the reasons endorsing grant funding.

In addition to the comprehensive overviews, all of the information reviewed by the Review Councils is available by clicking on the appropriate link in the portal. This information includes the full application, peer reviewer critiques, and the CEO affidavit for each proposal.

The approval of these grant recommendations is governed by a statutory process that requires two-thirds of the members present and voting to approve each recommendation. David Reisman, CPRIT's Chief Compliance Officer, will certify that the review process for the recommended grants followed CPRIT's award process prior to any Oversight Committee action.

The award recommendations will not be considered final until the Oversight Committee meeting on Wednesday, February 18, 2015. Consistent with the non-disclosure agreement that all Oversight Committee members have signed, the recommendations should be kept confidential and not be disclosed to anyone until the award list is publicly announced at the Oversight Committee meeting. I request that Oversight Committee members not print, email or save to your computer's hard drive any material on the portal. I appreciate your assistance in taking all necessary precautions to protect this information.

If you have any questions or would like more information on the review process or any of the projects recommended for an award, CPRIT's staff, including myself, Dr. Kripke and Dr. Goodman are always available. Please feel free to contact us directly should you have any questions. The programs that will be supported by the CPRIT awards are an important step in our efforts to mitigate the effects of cancer in Texas. Thank you for being part of this endeavor.

Sincerely,  
Wayne R. Roberts  
Chief Executive Officer

## Academic Research Award Recommendations –

The PIC unanimously recommends approval of 55 academic research grant proposals totaling \$66,922,094. The recommended grant proposals were submitted in response to one of five grant mechanisms: Individual Investigator Research Awards; Individual Investigator Research Awards for Cancer in Children and Adolescents; Individual Investigator Research Awards for Prevention and Early Detection; Recruitment of First-Time, Tenure-Track Faculty; and Recruitment of Rising Stars. The PIC followed the recommendations made by the Scientific Review Council (SRC). The SRC provided the prioritized list of recommendations for the Recruitment awards to the presiding officers on January 8, 2015.

The PIC is required to give funding priority, to the extent possible, to applications that meet one or more criteria set forth in V.T.C.A., TEX. HEALTH & SAFETY CODE § 102.251(a)(2)(C). The PIC determined that these academic research proposals met the following CPRIT funding priorities:

- could lead to immediate or long-term medical and scientific breakthroughs in the area of cancer prevention or cures for cancer;
- strengthen and enhance fundamental science in cancer research;
- ensure a comprehensive coordinated approach to cancer research and cancer prevention;
- are interdisciplinary or interinstitutional;
- address federal or other major research sponsors' priorities in emerging scientific or technology fields in the area of cancer prevention or cures for cancer;
- are matched with funds available by a private or nonprofit entity and institution or institutions of higher education;
- have a demonstrable economic development benefit to this state;
- enhance research superiority at institutions of higher education in this state by creating new research superiority, attracting existing research superiority from institutions not located in this state and other research entities, or enhancing existing research superiority by attracting from outside this state additional researchers and resources; and
- address the goals of the Texas Cancer Plan.

### Academic Research Grant Award Recommendations

App ID	Award Mechanism	Organization	Application Title	Budget
RP150006	IIRACCA	The University of Texas M. D. Anderson Cancer Center	Defining and Treating Targetable Lesions in AYA Acute Lymphoblastic Leukemia	\$1,989,950
RP150014	IIRAP	The University of Texas Health Science Center at Houston	Multi-component interventions for patients and providers to increase HPV vaccination in a network of pediatric clinics in Houston, TX	\$2,498,986
RP150030	IIRA	The University of Texas M. D. Anderson Cancer Center	Exploring molecular and immune mechanisms of response and resistance to combined BRAF/MEK inhibition in patients with high-risk resectable	\$900,000
RP150032	IIRACCA	Baylor College of Medicine	Developing New Combinatory Therapies for Pediatric High Grade Glioma	\$1,945,940
RP150053 *	IIRA	The University of Texas Southwestern Medical Center	Mechanisms of nuclear import and export in cancer	\$900,000
RP150079	IIRA	The University of Texas M. D. Anderson Cancer Center	Elucidating the evolution of the premalignant airway genome in space and time	\$886,173

RP150081	IIRACCA	Baylor College of Medicine	Genetic susceptibility to testicular germ cell tumors	\$1,406,791
RP150084	IIRA	The University of Texas M. D. Anderson Cancer Center	Role of PTEN feedback mechanism in cancer	\$900,000
RP150093	IIRA	The University of Texas M. D. Anderson Cancer Center	Targeting 17q23 amplicon in HER2- positive Breast Cancer	\$828,242
RP150094	IIRA	The University of Texas M. D. Anderson Cancer Center	Investigating the regulation of miRNA and lncRNAs by p63 in mammary tumor progression and metastasis	\$900,000
RP150102	IIRA	The University of Texas M. D. Anderson Cancer Center	Genome stability and immune diversity controlled by the POLQ pathway	\$900,000
RP150129	IIRACCA	Baylor College of Medicine	Drug Discovery and Mechanistic Studies of Protein Methylation Targeting Leukemia	\$1,733,813
RP150148	IIRA	The University of Texas M. D. Anderson Cancer Center	Identifying Drivers of Lung Metastasis in Triple Negative Breast Cancer	\$899,637
RP150164	IIRACCA	The University of Texas Southwestern Medical Center	Using imaging and computational tools to improve risk stratification in children with bone cancer	\$1,290,442
RP150166	IIRA	The University of Texas Health Science Center at San Antonio	Prostate Cancer Chemoprevention with Resveratrol	\$900,000
RP150179	IIRA	The University of Texas M. D. Anderson Cancer Center	Regulation of dormancy of metastatic prostate cancer cells by bone microenvironment	\$900,000
RP150195	IIRAP	The University of Texas M. D. Anderson Cancer Center	Mechanisms of DHA and EPA differential effects on colon cancer chemoprevention	\$920,926
RP150197	IIRA	Baylor College of Medicine	Understanding How NCOA6 Suppresses Endometrial Cancer by Inhibiting the Wnt/beta-Catenin Pathway	\$886,524
RP150224	IIRA	The University of Texas M. D. Anderson Cancer Center	Discovering the molecular mechanisms that determine replicative lifespan	\$892,104
RP150228	IIRAP	The University of Texas M. D. Anderson Cancer Center	Varenicline and Combined NRT for Initial Smoking Cessation and Rescue Treatment in Smokers: A Randomized Pilot Trial	\$1,493,464
RP150230	IIRA	The University of Texas Health Science Center at Houston	Counteracting tumor evasion of antibody immunity by a novel therapeutic strategy	\$900,000
RP150231	IIRA	The University of Texas M. D. Anderson Cancer Center	Function of Fibroblasts and Collagen I in Pancreas Cancer	\$898,811
RP150232	IIRA	Baylor College of Medicine	The Role of Progesterone Receptor in Early Stage Breast Cancer.	\$864,661
RP150235	IIRA	The University of Texas M. D. Anderson Cancer Center	Role of TBK1 in Regulating Dendritic Cell Function and Antitumor Immunity.	\$876,958
RP150242	IIRA	The University of Texas Southwestern Medical Center	Functional and structural characterization of a small chemical compound that arrests glioma stem cell growth with high activity and specificity	\$900,000
RP150245	IIRA	The University of Texas M. D. Anderson Cancer Center	EGFR Arginine Methylations: Biomarkers for Cetuximab Resistance in colon cancer	\$900,000
RP150277	IIRA	The University of Texas Health Science Center at San Antonio	Vertical targeting of the B cell receptor in leukemia and lymphoma	\$899,879

RP150282	IIRA	The University of Texas M. D. Anderson Cancer Center	Mechanisms of de novo and acquired resistance to therapeutic treatment of bone-metastatic prostate cancer	\$900,000
RP150292	IIRA	Baylor College of Medicine	Broad Shortening of 3' UTRs in Human Cancers: Methods, Target Genes and Functional Consequences	\$900,000
RP150293	IIRA	The University of Texas M. D. Anderson Cancer Center	Identification of clinically relevant targets for radiosensitization	\$899,280
RP150301	IIRACCA	The University of Texas M. D. Anderson Cancer Center	Epigenetics in Medulloblastoma Development and Therapeutics	\$1,871,708
RP150316	IIRA	The University of Texas M. D. Anderson Cancer Center	T-cell activating immunotherapy for indolent B-cell malignancies	\$852,595
RP150319	IIRA	The University of Texas M. D. Anderson Cancer Center	Leukemia inhibitory factor receptor signaling and function in cancer	\$900,000
RP150334	IIRACCA	Baylor College of Medicine	Personalized Functionalization of Pediatric High Grade Glioma	\$1,820,319
RP150343	IIRACCA	University of Houston	An ultra-sensitive nanomagnetic sensor for the early detection of anaplastic large cell lymphoma	\$1,929,710
RP150346	IIRA	The University of Texas at Austin	Targeting Twist1 for Prevention and Treatment of Non-Melanoma Skin Cancer	\$900,000
RP150356	IIRA	The University of Texas Southwestern Medical Center	Peripheral nerve tolerance to single-session stereotactic irradiation	\$897,779
RP150386	IIRA	The University of Texas Southwestern Medical Center	A Phase I Trial of Stereotactic Hypofractionated RadioAblative (HYDRA) Treatment of Advanced Laryngeal Cancer	\$860,540
RP150403	IIRA	The University of Texas M. D. Anderson Cancer Center	On the role of DEAR1 in the regulation of cell polarity and progression from DCIS to invasive breast cancer	\$899,846
RP150405	IIRA	The University of Texas M. D. Anderson Cancer Center	Tumor Cell Epithelial-Mesenchymal Transition in Regulating Immunosuppression and Metastasis in Lung Cancer	\$900,000
RP150408	IIRA	The University of Texas Health Science Center at San Antonio	Cellular mechanisms of chemotherapy-induced peripheral neuropathy	\$844,746
RP150416	IIRACCA	Texas Tech University Health Sciences Center	Translational Investigations On Fenretinide and Safingol For Pediatric Cancer Use	\$1,999,415
RP150421	IIRAP	Texas Engineering Experiment Station	High-throughput Screening and Detection of Circulating Tumor Cells	\$1,135,450
RP150440	IIRA	Baylor College of Medicine	Effects of hormonal therapy on subclonal evolution of breast tumors with ESR1 mutations	\$899,805
RP150445 **	IIRACCA	The University of Texas Health Science Center at San Antonio	Ewing's sarcoma, a homologous recombination defective disease	\$2,000,000
RP150449	IIRAP	The University of Texas Medical Branch at Galveston	Noninvasive multiscale imaging for optical biopsy in epithelial cancers	\$852,748
RP150451 ***	IIRA	Baylor College of Medicine	SRC-2 driven "Metabolic Switch" in metastatic prostate cancer- Prognostic and Therapeutic implications	\$900,000

RP150454	IIRA	Texas A&M University	Tumor Suppression Through the cGAMP/STING Pathway	\$900,000
RP150456	IIRA	The University of Texas Southwestern Medical Center	TAMU-UT Southwestern Partnership for Breast Imaging and Spectroscopy at 7 Tesla	\$897,311
RP150485	IIRA	The University of Texas Southwestern Medical Center	Translating Online Adaptive Radiotherapy from Lab to Clinical Practice	\$858,356
RP150498	IIRA	The University of Texas Southwestern Medical Center	Harnessing the Cytosolic DNA Sensing Pathway for Cancer Immunotherapy	\$889,185

\* RP150053 - Budget will be adjusted down during contracting to accommodate a change in the Scope of Work (removal of specific Aim 3) as recommended by the peer review panel. The total amount requested was \$900,000.

\*\*RP150445 - Budget will be adjusted down during contracting to accommodate a reduction in personnel and associated supplies and materials as recommended by the peer review panel. The total amount requested was \$2,000,000.

\*\*\*RP150451 - Budget will be adjusted down during contracting to accommodate a change in the Scope of Work (removal of specific Aim 3) as recommended by the peer review panel. The total amount requested was \$900,000.

\*\*\*\*RP150408 - Budget will be adjusted down during contracting to accommodate a change in the Scope of Work (removal of specific Aim 3) as recommended by the peer review panel. The total amount requested was \$844,746.

### Academic Research Recruitment Grant Award Recommendations

App ID	Organization/Company	Candidate	Mechanism	Budget Requested
RR150032	The University of Texas Southwestern Medical Center	Dr. Jenna L. Jewell	RFT	\$2,000,000
RR150033	The University of Texas Southwestern Medical Center	Dr. Vincent S. Tagliabracci	RFT	\$2,000,000
RR150025	The University of Texas Southwestern Medical Center	Dr. H. Charles Manning	RRS	\$4,000,000
RR150038	Texas A&M University	Dr. Jonathan T. Sczepanski	RFT	\$2,000,000

\*RRS = Recruitment of Rising Star, RFT = Recruitment of First Time Tenure Track, REI = Recruitment of Established Investigator

*Withdrawn*

*W 2-18-15*

## Product Development Award Recommendations –

The PIC unanimously recommends approval of four product development grant proposals totaling \$48,452,265. The recommended grant proposals were submitted in response to the New Company Product Development Awards Request for Applications. The PIC followed the recommendations made by the Product Development Review Council (PDRC). The PDRC provided the prioritized list of recommendations for the product development awards to the presiding officers on January 21, 2015.

The PIC is required to give funding priority, to the extent possible, to applications that meet one or more criteria set forth in V.T.C.A., TEX. HEALTH & SAFETY CODE § 102.251(a)(2)(C). The PIC determined that these product development proposals met the following CPRIT funding priorities:

- could lead to immediate or long-term medical and scientific breakthroughs in the area of cancer prevention or cures for cancer ;
- strengthen and enhance fundamental science in cancer research;
- ensure a comprehensive coordinated approach to cancer research and cancer prevention;
- address federal or other major research sponsors' priorities in emerging scientific or technology fields in the area of cancer prevention or cures for cancer;
- are matched with funds available by a private or nonprofit entity and institution or institutions of higher education;
- are collaborative between any combination of private and nonprofit entities, public or private agencies or institutions in this state, and public or private institutions outside this state;
- have a demonstrable economic development benefit to this state;
- expedite innovation and product development, attract, create, or expand private sector entities that will drive a substantial increase in high-quality jobs, and increase higher education applied science or technology research capabilities; and
- address the goals of the Texas Cancer Plan.

### Product Development Grant Award Recommendations

Application ID	Company Name	Project	Requested Budget
DP150021	NanoTx Therapeutics	Development of Rhenium Nanoliposomes for Cancer Therapy	\$ 2,000,000
DP150029	Immatics Biotechnologies	Personalized Cellular Immunotherapy against Novel Cancer Targets	\$19,652,175
DP150031	Medicenna Therapeutics, Inc.	A Multi-Targeted Approach for Recurrent Glioblastoma and Other Aggressive Cancers: Exploiting the Potential of IL-4 Fusion Proteins Treatment of Cancer	\$14,140,090
DP150039	Armada Pharmaceuticals, Inc.	New Company Formation for the Development of Anti-Cancer Antibody – Drug Conjugate Therapeutics	\$12,750,000